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Vitamin D plays a significant role in the immune system modulation and may confer a protective role in autoimmune diseases.
We conducted a case-control study to compare 25(OH)D levels in patients with BD who were managed at a regional rheumatology
programme in the midwest region of Ireland compared to matched controls. Healthy controls were selected from the Irish health
system andmatched in 1 : 5 ratio for age, sex, and themonth of the year. 25(OH)D levels<20 nmol/Lwere classified as deficient while
levels between 20 and 40 nmol/Lwere classified as insufficient. Differences between groups were assessed usingMann–Whitney test
and associations between cases and controls were expressed as odds ratios and 95% confidence intervals. Nineteen patients with BD
were comparedwith 95 controlsmatched by age, sex, andmonth of blood draw. 25(OH)D levels were significantly higher in patients
in BD than in matched controls (median values: 45 nmol/L versus 22 nmol/L, 𝑝 < 0.005) and tended to be lower in patients with
active disease than in those without (median values: 35 nmol/L (IQR: 22.75–47.25 nm/L) versus 50 nmol/L (IQR: 35–67 nmol/L),
𝑝 = 0.11). Compared to controls, patients with BD were significantly less likely to have 25(OH)D deficiency or insufficiency (OR:
0.09, 95% CI: 0.03–0.28, 𝑝 < 0.001). Our findings suggest a possible role for 25(OH)D in modifying the inflammatory response in
BD and uncover a potential opportunity to assess whether correction of Vit D deficiency confers protective benefits.
1. Introduction
Behc¸et’s disease (BD) is classified among vasculitides with
a unique characteristic of having a predilection for both
arteries and veins and manifesting with distinct clinical
characteristics. Despite having a considerable geographical
variation with the highest prevalence seen along the Silk
Road, BD is seen throughout the world including European
countries with latitudes above 45∘ north. Ireland is a country
with a temperate maritime climate strongly influenced by
the Atlantic Ocean due to its proximity at the periphery of
northwest Europe at a high latitude of 51–55∘ north, with a
relatively low sunshine exposure throughout the year [1].
Vitamin D (Vit D) is a major fat-soluble vitamin that is
essential for normal immune function and a large body of
evidence now implicates Vit D in the pathogenesis of several
inflammatory diseases including BD [2–16].Themain source
ofVitD is from the ultraviolet B- (UVB-) induced synthesis in
the skin, which is then activated via two hydroxylation steps
in the liver and kidney. Studies have shown that exposing
5% of the body surface in fair-skinned persons 2 to 3 times
a week for 5 minutes of noontime summer sun exposure is
equivalent to intake of 430 IU/d of Vit D, which satisfies the
recommended Vit D intake of 200 IU/d for young adults [17].
The recommended intake is 400 IU/d for persons aged 51 to
70 years and 600 IU/d for those above 70 years of age [18].
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A serum Vit D level of ≥30 ng/mL (75 nmol/L) is considered
adequate to limit the release of parathyroid hormone or
promote the intestinal absorption of calcium [19, 20].
Recent studies fromMediterranean countries and the Far
East have uncovered potentially important links between Vit
D and BD [9–16, 21–23]. Interestingly, the findings indicate
an inverse correlation between Vit D and BD [9–15] with
higher levels of Vit D correlating with lower levels of disease
activity [12, 14, 16]. It is hypothesized that low levels of Vit
D suppress T-regulatory cells (Tregs) activity, cause skewing
of the Th1/Th2 balance towards Th1, and impair endothelial
function [10, 12]. However, not all studies have confirmed this
association. Observational studies from Turkey and Tunisia
found no significant differences between Vit D levels in cases
with BD and matched healthy controls [21, 22], while con-
trastingly a study from Iran found higher Vit D levels among
patients with BD [23].
The aim of our study was to determine the relationship
betweenVit D status and BD in an Irish population and assess
whether Vit D levels varied according to disease activity.This
study is the first to explore the association between Vit D and
BD in a Northern European population.
2. Methods
2.1. Study Design. We conducted a case-control study of
patients with BD and compared them to healthy controls
selected from the Irish health system. Cases included all
patients with BD who were managed in a regional rheuma-
tology programme at University Hospital Limerick, a ter-
tiary centre located in the midwest region of Ireland. All
cases satisfied the International Study Group Criteria for
Behc¸et’s Disease (ISGBD) or the International Criteria for
Behc¸et’s Disease (ICBD). Medical records and electronic data
including clinical and laboratory parameters of all cases were
reviewed. Exclusion criteria include other rheumatological or
bone/skeletal diseases or other diseases with higher inflam-
matory status, history of chronic kidney disease or other
chronic systemic diseases, malignancies, and limited physical
activity. Patients were also excluded if they received Vit D
supplementation or medications that interfered with Vit D
metabolism including calcium supplements, cytotoxic drugs,
anticonvulsants, bisphosphonates, or thyroxine, but not
glucocorticoids and disease-modifying antirheumatic drugs
(DMARDs). Active disease in BDwas defined as the presence
of any characteristic symptoms including mucocutaneous,
visceral, ocular, or skin lesions necessitating initiation or dose
increment of systemic steroids and/or immunosuppressive
therapy. Healthy controls (𝑛 = 95) were selected from a
register of patients in the health system from years 2013
and 2014. Blood samples from controls were matched with
cases based on age, sex, and month of blood draw in a 1 : 5
ratio. Control subjects had normal concentrations of serum
creatinine, haemoglobin, and serum albumin.
2.2. Vitamin D Assessment. Total serum 25-hydroxyvitamin
D (25(OH)D) level was measured by using competitive
chemiluminescence immunoassays (DiaSorin, Dietzenbach,
Germany) with interassay coefficient of variation (CV) of
6.8% [24, 25]. Levels less than 20 nmol/Lwere defined asVitD
deficient and between 20 and 40 nmol/L as Vit D insufficient,
with “normal” defined as levels more than 40 nmol/L. The
study was approved by the local ethics committee and is in
accordance with the Declaration of Helsinki.
2.3. Statistical Analysis. Vit D levels were not normally
distributed; therefore, median and interquartile ranges were
used to describe distributions between cases and controls.
Nonparametric statistics (Mann–Whitney 𝑈 test) were used
to compare serumVit D levels between patients and controls.
Odds ratios (OR) and 95%confidence intervals (95%CI)were
used to determine the likelihood of Vit D deficiency and Vit
D insufficiency for cases versus controls using multivariate
logistic regression. 𝑝 values of <0.05 were considered statis-
tically significant. Statistical analyses were performed using
SPSS 22.0 software for Macintosh.
3. Results
A total of 19 Caucasian patients with BD were included in
the study sample (5 males, 14 females, median age of 37.5
years, interquartile range (IQR): 24.3–51.2 years). 15 patients
were in clinical remission while 4 patients had evidence of
active disease. Baseline characteristics of the study population
are reported in Tables 1 and 2. There were no statistically
significant differences between cases and the control group
with regard to age, sex, and time of blood draw. Disease
duration varied between 0.25 and 30 years (mean: 8.07 years).
Median serum concentrations of 25(OH)D for patients
with BD and controls were 45 nmol/L (IQR: 33–65 nmol/L)
and 22 nmol/L (IQR: 15–31 nmol/L), respectively, p < 0.005.
The median 25(OH)D levels also tended to be lower among
patients with active BD as compared to those with inactive
disease, 35 nmol/L (IQR: 22.75–47.25 nmol/L) and 50 nmol/L
(IQR: 35–67 nmol/L), respectively, but this did not reach
statistical significance (𝑝 value = 0.11) (Table 3). Similarly,
the prevalence of 25(OH)D deficiency and insufficiency was
significantly lower in BD compared to matched controls (0%
versus 42% for 25(OH)D deficiency and 6% versus 36% for
25(OH)D insufficiency, 𝑝 < 0.005).
In the unadjusted analysis, compared to controls, patients
with BD were significantly less likely to have 25(OH)D
deficiency or insufficiency with the unadjusted analysis odds
ratio (OR) 0.10 (0.03, 0.30). With adjustment for age, sex,
and month of blood draw, the relationship was even more
robust (OR: 0.09 (0.03, 0.28), 𝑝 < 0.001). Women were more
likely than men to have Vit D deficiency (OR: 3.01, 95% CI:
1.10–8.26) (Table 4).
4. Discussion
In this Irish study, we report significant differences in the
concentrations of Vit D levels among patients with BD
compared to healthy controls from the health system. In
keeping with the previous Iranian study [23], our study
found significantly and substantially higher 25(OH)D levels
in patients with BD than in those without. The magnitude of
the differencewas quite substantial and our analysis indicated
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Table 1: Demographics and clinical characteristics of BD patients and healthy controls.
Variables BD patients (𝑛 = 19) Controls (𝑛 = 95) 𝑝 value
Age (years) 37.5 37.4 0.924
Median (Q1–Q3) (24.3–51.2) (24.1–51.4)
Female, 𝑛 (%) 14 (73.68) 70 (73.68) N/A
Serum 25(OH)D levels (median) (nmol/L) 45.0 22.0 0.001
IQR (Q1–Q3) (33.0–65.0) (15.0–31.0)
25(OH)D deficiency (<20 nmol/L), 𝑛 (%) 0 (0) 42 (44.2)
25(OH)D insufficiency (20–40 nmol/L), 𝑛 (%) 6 (31.6) 36 (37.9)
On prednisolone, 𝑛 (%) 8 (42.1) Nil N/A
<7.5mg daily, 𝑛 (%) 8 (42.1)
≥7.5mg daily, 𝑛 (%) 0 (0)
DMARDs, 𝑛 (%) 15 (78.9) Nil N/A
On conventional DMARD, 𝑛 (%) 0 (0)
On anti-TNF therapy, 𝑛 (%) 15 (78.9)
Values are median and IQR, or numbers (𝑛) and percentage (%) for counts. 25(OH)D: 25-hydroxyvitamin D; N/A: not applicable; IQR: interquartile range;
Q1: 25th quartile; Q3: 75th quartile.
Table 2: Patients’ clinical characteristics, treatment, and their vitamin D status.
Number G Age OA GU OI CI PP VI GI ENT DA 25(OH)D ESR CRP
1 F 33 + + − + − − − + − 76 6 <5
2 M 51 + + + + + − + + − 71 7 7
3 F 35 + + − + − − − + A 42 25 5
4 F 23 + + − + − − − + − 45 11 <5
5 F 17 + + + + − − − − − 50 6 <5
6 M 48 + + + + − + − − − 65 12 <5
7 M 56 + − + + − − − + − 58 2 <5
8 F 37 + + − + − − − − − 67 12 <5
9 F 38 + + − − + − − − − 41 8 <5
10 M 34 + + − + − − − − − 76 17 <5
11 F 37 + + − + − − − − − 33 5 <5
12 F 52 + + − + − + − − A 28 28 <5
13 F 81 + + + + − − − − − 41 14 <5
14 F 66 + + − + − − + − − 35 33 <5
15 M 45 + + − − − + − − − 29 7 <5
16 F 37 + + − + − − − − A 21 28 25
17 F 23 + + + + − − − − − 53 5 <5
18 F 21 + + − + − − − − − 26 13 <5
19 F 24 + + − + − − − − A 49 14 <5
G: gender; OA: oral aphthosis; GU: genital ulcers; OI: ocular involvement; CI: cutaneous involvement; PP: pathergy phenomenon; VI: vascular involvement;
GI: gastrointestinal involvement; ENT: otolaryngeal involvement; DA: disease activity; A: active disease; 25(OH)D: 25-hydroxyvitamin D (nmol/L); ESR:
erythrocyte sedimentation rate (mm/hour); CRP: C-reactive protein (mg/L).
Table 3: Comparison of 25(OH)D levels between patients with active and inactive Behc¸et’s disease.
Variables Active BD (𝑛 = 4) Inactive BD (𝑛 = 15) p value
Serum 25(OH)D levels (median) (nmol/L) 35.0 50.0 0.11
(IQR1–IQR3) (21.0–42.0) (35.0–67.0)
25(OH)D deficiency (<20 nmol/L), 𝑛 (%) 0 (0) 0 (0)
25(OH)D insufficiency (20–40 nmol/L), 𝑛 (%) 2 (50.0) 4 (26.7)
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Table 4: Odds ratio of 25(OH)D deficiency in cases versus controls.
Variables Unadjusted OR (95% CI) 𝑝 value Adjusted OR (95% CI) 𝑝 value
Sex
Female versus male 2.44 (1.00, 6.00) 0.051 3.01 (1.1, 8.26) 0.032
Group
Cases (with BD) versus controls 0.10 (0.03, 0.30) <0.001 0.09 (0.03, 0.28) <0.001
that patients with BD were over 10-fold less likely to have
Vit D deficiency compared to controls without BD.Moreover,
our study also suggested that patients with active BD tended
to have lower Vit D levels compared to those with inactive
disease. Our findings suggest a possible role for 25(OH)D in
modifying the inflammatory response in BD and uncover a
potential opportunity to assess whether correction of Vit D
deficiency confers protective benefits.
The finding of higher concentrations of Vit D in patients
with BD compared to control patients was an unusual
yet intriguing observation. The threshold value of Vit D
considered to be adequate for human health is 50 nmol/L
and therefore the majority of both BD patients and controls
had levels that were below this threshold limit [26]. Notwith-
standing this, cases with BD experienced significantly higher
levels than controls without the disease. Evenmore intriguing
is the observation that patients with active BD tended to have
lowerVit D levels than thosewithout. It is possible that higher
levels of Vit D are immunomodulatory and downregulate
inflammatory pathways commonly associated with BD and
thereby are protective against disease flares.The small sample
size clearly makes it difficult to demonstrate significance but
our observations support the findings from other published
studies [12, 14, 16] and suggest that serum concentrations of
25(OH)D in subjects with BD correlate inversely with disease
activity.
Another interesting finding in our study is that the
majority of subjects in the control group were either Vit D
insufficient or deficient. Ireland is located at the high latitudes
of 51–55∘ north and receives between 1100 and 1600 hours of
sunshine each year [27]. Due to its geographical position in
Northwest Europe and its proximity to the Atlantic Ocean
resulting in a low-pressure system and moderation of the
climate, Ireland is said to have a maritime climate where
summers are not too hot and winters are not too cold. The
average amount of rainfall in the western region of Ireland
is up to 225 days a year while the cloud immersion almost
completely covers the skies for more than 50 percent of the
time [27]. These combined factors together with possible
uses of sunscreens ultimately result in inadequate quantity
and ineffective quality of UV irradiation that may explain
why hypovitaminosis D abounds within the Irish population
[28, 29].
Vit D contributes to the regulation of the proliferation,
differentiation, and function of immune cells, both directly
and indirectly [30–32]. The perspective role of Vit D as an
immunoregulatory hormone stemmed from in vitro studies
of its metabolism by immune cells in the early 1980s [33, 34]
and was further supported by the works of Fritsche and Van
Etten and their respective colleagues who identified the Vit
D receptor (VDR) in the immune cells such as neutrophils,
dendritic cells, and activated lymphocytes [35], proving that
Vit D was potently able to modulate a range of immune cell
functions [36], respectively.
Vit D has been shown to enhance the effect of den-
dritic cells, macrophages, and monocytes and has been
demonstrated to downregulate cellular response to tumor
necrosis factor-alpha (TNF-𝛼), B-cell antibody production,
and proinflammatory cytokines such as interleukin-1 (IL-
1), IL-2, IL-6, IL-12, and interferon-gamma (IFN-𝛾) [37–
42]. Its receptor, VDR, is a nuclear hormone receptor that
regulates the p450 enzymes and interacts with various inter-
connected lipid metabolism and immune signaling pathways
that have instrumental roles in immunity including peroxi-
some proliferator-activated receptor-alpha (PPAR-𝛼), PPAR-
𝛾, NF-𝜅B, p38 mitogen-activated protein kinase (MAPK),
transforming growth factor-beta (TGF-𝛽), and eicosanoid
synthesis [43]. It is also a ligand-regulated transcription factor
ofmany target genes, namely, the natural endogenous antimi-
crobial peptides (AMPs) cathelicidin and 𝛽-defensin: both
crucial in shaping the gut microbiota [43], barrier defense,
and maintaining the integrity of the gut mucosa [44, 45].
These overall immunoregulatory effects underline Vit D as a
key mediator of innate and adaptive immunity.
In addition, there has also been a paradigm shift regard-
ing the different functions of Vit D, including its essential
role in the skin [46–51]. Skin cells such as keratinocytes and
fibroblasts express VDR, an absolute prerequisite for regula-
tion of genomic effects of Vit D and its other analogs [47]. A
randomized, double-blind placebo-controlled study demon-
strated that Vit D supplementation resulted in a significant
improvement in parameters of diabetic foot ulcers at 12 weeks
compared to placebo [48]. Other studies have demonstrated
the positive effect of Vit D in tissue formation and remodeling
[49–51]. The recurrent, relapsing, and remitting nature of
Behc¸et’s disease (BD), especially the orogenital ulcers and
cutaneous manifestations, and the fact that wound healing is
a dynamic process which involves phases of inflammation,
tissue formation, and remodeling [52] implicate Vit D as
possibly one of the key players in the pathogenesis of BD.
The Vit D pathway is now strongly implicated to be
involved in the pathogenesis of inflammatory diseases such as
inflammatory arthritis, lupus, and BD [2–16]. Furthermore,
VDR gene polymorphisms have been observed to be sig-
nificantly associated with an increased susceptibility risk in
different BD populations [53–56]. Recently, Kahraman et al.
demonstrated elevated numbers of circulating extracellular
vesicles (EVs), novel mediators of distant cellular commu-
nication in BD patients, and observed significantly higher
levels of cathelicidin in plasma of active BD patients, with
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two-thirds of them being associated with the EVs and
cytokine production, correlating themwith the disease activ-
ity [57].
Gut microbiota (GM) dysbiosis characterized by the
reduction of the GM ecosystem diversity and composi-
tion has been implicated in the proinflammatory features
of several autoimmune disorders including immunological
diseases outside of the gut [58, 59], and this impaired
microbiome-host interaction seems to play a role in the
pathogenesis of BD [60–62]. Recently, Wang et al. in their
comprehensive analysis of genome-wide host-microbiota
associations discovered significant associations between gut
microbial characteristics and the VDR gene [63]. In another
study, Yuk et al. demonstrated cathelicidin as the link between
autophagy and Vit D mediated innate immunity [64]. The
relationship between autophagy, which not just maintains the
gut intracellular homeostasis but also promotes immunity
in symbiosis with the VDR, and the gut microbiota shapes
the intestinal immune response and the disarray of this
interaction may play a crucial part in the pathogenesis of BD.
We acknowledge some inherent limitations in the present
study and consequently definitive conclusions are limited.
First, the relatively small sample size of our cohort with
BD and the variability in the duration of disease posed a
limitation in our study. However, the number of patients in
this study is an accurate reflection of the low prevalence of
BD in this Northern European geographical region. Further
studies including collaborative efforts involving other BD
cohorts may provide a greater insight into this specific area.
Second, our analysismay be confounded by other factors such
as body mass index and the differences in the sun exposure
of cases (and controls) which may vary according to lifestyle,
the use of sunscreen, and overall health. Third, we were also
unable to adjust for season variation in Vit D as the study was
conducted over 10 months to coincide with outpatient visits.
However, we attempted to account for this confounder in our
analysis by limiting the selection of controls only to thosewho
had Vit D levels assessed during the same time period.
The strength of our study is the comparison with a
control population who were selected from patients within
the health system based on age, gender, and timing of taking
the sample. Despite insufficient and inconclusive evidence
in the literature, there is a growing appreciation and basis
to suggest that Vit D supplementation could represent an
essential adjuvant treatment in active inflammatory patients
who are also found to be deficient or insufficient of Vit D.
The results of our study, despite its limitations, may provide
some basis to support this hypothesis. Further intervention
studies however are needed to prove a beneficial effect of Vit
D supplementation among BD patients.
In summary, our study found evidence of elevated
25(OH)D levels in patients with BD compared to controls
in the health system. Patients with BD were over 10-fold
less likely to have Vit D deficiency adjusting for age, sex,
and timing of blood samples. Vit D levels tended to be
also lower among those with active disease than among
those without. Our findings suggest that Vit D may be a
potential suppressor of the inflammatory response in BD.
The contribution of Vit D to the pathogenesis of BD and
as a therapeutic intervention deserves further investigation.
Studies of larger size are required to explore the hypothesis
suggested here.
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